Is DVA a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The buyback is the growth engine, with revenue (ttm) at ~$14.0 billion (up ~6.4% year over year). The bear case rests on payer mix is the dominant risk and it is currently moving the wrong way: the expiration of enhanced ACA premium subsidies is pushing patients out of commercial plans and into government coverage, which management sized as roughly a $40 million headwind in 2026 with a larger one expected in 2027. Analysts covering it are spread from $145.00 to $270.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Payer mix is the dominant risk and it is currently moving the wrong way: the expiration of enhanced ACA premium subsidies is pushing patients out of commercial plans and into government coverage, which management sized as roughly a $40 million headwind in 2026 with a larger one expected in 2027. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $145.00, -23.2% from the $188.69 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The buyback is the growth engine. DaVita pays no dividend and directs essentially all free cash flow into repurchases. The most optimistic analyst target on DVA is $270.00, +43.1% from the $188.69 price. That figure is only reachable if this thesis works close to its best case.

Payer mix is the dominant risk and it is currently moving the wrong way: the expiration of enhanced ACA premium subsidies is pushing patients out of commercial plans and into government coverage, which management sized as roughly a $40 million headwind in 2026 with a larger one expected in 2027. Revenue per treatment fell about $2 sequentially in Q2 2026 on that mix shift plus lower phosphate binder revenue, and management guided to slightly negative revenue per treatment growth in the second half, while patient care costs per treatment stayed elevated. Leverage sits around 3.37 times consolidated EBITDA, at the upper end of the stated 3.0 to 3.5 times target, so the buyback, the debt load and the earnings base are tightly coupled and a payer-mix shock compresses all three at once. Berkshire Hathaway's roughly 45% position is both an anchor and an overhang, since the repurchase agreement means a meaningful slice of company cash is committed to buying one holder's shares rather than allocated freely. Longer term, wider GLP-1 use slowing chronic kidney disease progression, transplant advances, government reimbursement rate decisions, labor cost inflation at the clinic level, and cybersecurity exposure after the April 2025 ransomware incident all sit on the risk register. The most pessimistic published target is $145.00, -23.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

DaVita is one of two companies that dominate US outpatient dialysis, running more than 3,000 clinics for patients with end-stage kidney disease. Berkshire Hathaway is its largest shareholder.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The buyback is the growth engine) stalling in the reported numbers rather than in the narrative, the risk above (payer mix is the dominant risk and it is currently moving the wrong way: the expiration of enhanced ACA premium subsidies is pushing patients out of commercial plans and into government coverage, which management sized as roughly a $40 million headwind in 2026 with a larger one expected in 2027) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

DaVita provides dialysis for people with end stage renal disease, whose kidneys no longer filter their blood. As of June 30, 2026 it served roughly 298,500 patients at 3,266 outpatient centers, 2,671 in the US and 595 across 14 other countries. Patients typically come in three times a week and DaVita bills a payer per treatment. It also runs Integrated Kidney Care, a value-based arm taking financial risk on patient outcomes.

DVA trades on the NYSE and can be bought as whole or fractional shares at any major US broker. It is a member of the S&P 500, so most broad index funds already hold it in small weight, and healthcare sector ETFs hold it as well. In Walnut you can also hold it as one constituent inside a thematic basket alongside other kidney care, dialysis or defensive healthcare names, with a target weight you set.

No. DaVita has never paid a common dividend and returns capital exclusively through share repurchases. In the first half of 2026 alone it repurchased about 5.24 million shares for roughly $751 million at an average cost near $142.77. For an investor, that means total return depends entirely on price appreciation and the per-share effect of a shrinking float, with no income component.